RT Journal Article
SR Electronic
T1 Qatar Genome: Insights on Genomics from the Middle East
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.19.21263548
DO 10.1101/2021.09.19.21263548
A1 Mbarek, Hamdi
A1 Gandhi, Geethanjali Devadoss
A1 Selvaraj, Senthil
A1 Al-Muftah, Wadha
A1 Badji, Radja
A1 Al-Sarraj, Yasser
A1 Saad, Chadi
A1 Darwish, Dima
A1 Alvi, Muhammad
A1 Fadl, Tasnim
A1 Yasin, Heba
A1 Alkuwari, Fatima
A1 Razali, Rozaimi
A1 Aamer, Waleed
A1 Abbaszadeh, Fatemeh
A1 Ahmed, Ikhlak
A1 Mokrab, Younes
A1 Suhre, Karsten
A1 Albagha, Omar
A1 Fakhro, Khalid
A1 Badii, Ramin
A1 Ismail, Said I.
A1 Althani, Asma
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/28/2021.09.19.21263548.abstract
AB Despite recent biomedical breakthroughs and large genomic studies growing momentum, the Middle Eastern population, home to over 400 million people, is under-represented in the human genome variation databases. Here we describe insights from phase 1 of the Qatar Genome Program which whole genome sequenced 6,045 individuals from Qatar. We identified more than 88 million variants of which 24 million are novel and 23 million are singletons. Consistent with the high consanguinity and founder effects in the region, we found that several rare deleterious variants were more common in the Qatari population while others seem to provide protection against diseases and have shaped the genetic architecture of adaptive phenotypes. Insights into the genetic structure of the Qatari population revealed five non-admixed subgroups. Based on sequence data, we also reported the heritability and genetic marker associations for 45 clinical traits. These results highlight the value of our data as a resource to advance genetic studies in the Arab and neighbouring Middle Eastern populations and will significantly boost the current efforts to improve our understanding of global patterns of human variations, human history and genetic contributions to health and diseases in diverse populations.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All QBB participants signed an Informed Consent Form prior to their participation; QBB study protocol ethical approval was obtained from the Hamad Medical Corporation Ethics Committee in 2011 and continued with QBB Institutional Review Board (IRB) from 2017 onwards and it is renewed on an annual basis (IRB protocol number, QF-QGP-RES-PUB-002).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe informed consent given by the study participants does not cover posting of participant level phenotype and genotype data of Qatar Biobank/Qatar Genome Project in public databases. However, access to QBB/QGP data can be obtained through an established ISO-certified process by submitting a project request at https://www.qatarbiobank.org.qa/research/how-to-apply which is subject to approval by the QBB IRB committee. https://www.qatarbiobank.org.qa/research/how-apply